Jakura 5 Tablet contains Tofacitinib 5mg, an oral Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients. Tofacitinib works by selectively inhibiting JAK enzymes, which play a crucial role in the signaling pathways involved in the inflammatory and immune responses. By modulating these pathways, Jakura 5 helps reduce inflammation, joint damage, and other symptoms associated with autoimmune conditions. It is typically prescribed when patients have had an inadequate response or intolerance to methotrexate or other conventional disease-modifying antirheumatic drugs (DMARDs). The recommended dosage should be individualized based on the patient’s clinical response and tolerability, with regular monitoring for adverse effects. Common side effects include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. Serious adverse reactions may involve increased risk of infections, malignancies, and thrombosis, necessitating careful patient evaluation prior to and during treatment. Jakura 5 is contraindicated in patients with active infections and should be used cautiously in those with a history of chronic or recurrent infections. Regular laboratory monitoring, including complete blood counts and liver function tests, is advised to ensure patient safety during therapy.

Dosage & How to Use